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Glaucoma, a main cause of blindness in the developed world, is characterized by progressive degeneration of retinal ganglion cells
(RGCs), resulting in irreversible loss of vision. Although members of the neurotrophin gene family in various species are known to
support the survival of numerous neuronal populations, including RGCs, it is less clear whether they are also required for survival
and maintenance of adult neurons in humans. Here, we report seven different heterozygous mutations in the Neurotrophin-4 (NTF4)
gene accounting for about 1.7% of primary open-angle glaucoma patients of European origin. Molecular modeling predicted a decreased
afﬁnity of neurotrophin 4 protein (NT-4) mutants with its speciﬁc tyrosine kinase receptor B (TrkB). Expression of recombinant NT-4
carrying the most frequent mutation was demonstrated to lead to decreased activation of TrkB. These ﬁndings suggest a pathway in
the pathophysiology of glaucoma through loss of neurotrophic function and may eventually open the possibility of using ligands
activating TrkB to prevent the progression of the disease.Introduction
Gradual visual impairment due to progressive loss of
retinal ganglion cells (RGCs), axons, and glial cells causing
a typical form of atrophy of the optic nerve characterizes
glaucoma.1–4 Elevated intraocular pressure (IOP) has been
suggested as a risk factor, and as a result, all current treat-
ments aim at lowering IOP as a means of slowing the
progression of the degenerative process.5,6 However,
patients often fail to show much improvement even after
IOP reduction, whereas others develop glaucoma in the
absence of elevated IOP. Patients showing no anatomical
impairment of aqueous humor outﬂow in the chamber
angle are referred to as having the open-angle form of
the disease (POAG [MIM 137760]), which typically mani-
fests itself after the age of 40.7 A family history of the
disease has long been recognized as a risk factor, suggesting
that speciﬁc gene defects contribute to disease pathogen-
esis of POAG, a condition that exhibits high clinical
heterogeneity. In some families, glaucoma segregates as
a Mendelian trait with reduced penetrance and variable
expressivity, but most cases are sporadic, suggesting a
multifactorial contribution in the etiology of the disease.8
Classical linkage approaches in POAG families has allowed
the delineation of 14 loci (GLC1A-1N),9 and glaucoma-
causing genes have been identiﬁed in three of them,
includingmyocilin (MYOC/GLC1A [MIM 601652]);10 opti-The Amerneurin (OPTN/GLC1E [MIM 602432]);11 and WD repeat
domain 36 (WDR36/GLC1G [MIM 609669]).12 Each of
these genes is responsible for a small proportion of POAG
cases (1%–5%). In addition, heterozygous loss-of-function
mutations in CYP1B1 (MIM 601771) constitute a risk
factor (odds ratio [OR] ¼ 5.8) for development of
POAG.13–16 Recessive loss-of-function CYP1B1 mutations
are usually found in newborns with primary congenital
glaucoma (MIM 231300).
Recent reports have suggested for neurotrophins and
their receptors a protective role in RGCs.17–19 In particular,
studies of animal models have shown an increase in retinal
expression of neurotrophins and their receptors after expo-
sure to high IOP,20 glutamate,21 and nitric oxide (NO).22
Given that elevated IOP, ischemia, release of cytotoxins
such as glutamate and NO, and vascular dysfunction are
all implicated in glaucoma, impaired neurotrophin
signaling to retinal cells or lack of trophic support in the
retina by neurotrophins can be postulated in the develop-
ment of the disease. To our knowledge, however, genetic
variation in neurotrophins or their receptors has not yet
been investigated in glaucoma.
In this study, we focused on NT-4, a member of the neu-
rotrophin protein family comprising four members in
mouse and human.23,24 Like brain-derived neurotrophic
factor (BDNF), NT-4 also activates the receptor TrkB on
RGCs and prevents their death in vitro and after axotomy1Institute of Human Genetics, 2Department of Ophthalmology, 3Institute of Biochemistry, 4Animal Physiology, University Erlangen-Nuremberg, 91054
Erlangen, Germany; 5Biozentrum, University of Basel, CH-4056 Basel, Switzerland; 6Molecular Genetics Laboratory, University Eye Hospital, 72076
Tu¨bingen, Germany; 7University Eye Hospital, 97080 Wu¨rzburg, Germany; 8Department of Epidemiology, 9Department of Ophthalmology, Erasmus
University Medical Center, Rotterdam, The Netherlands; 10Institute of Human Genetics, University of Regensburg, 93053 Regensburg, Germany
11Present address: MGZ-Medical Genetics Centre, 80335 Munich, Germany
*Correspondence: reis@humgenet.uni-erlangen.de
DOI 10.1016/j.ajhg.2009.08.016. ª2009 by The American Society of Human Genetics. All rights reserved.ican Journal of Human Genetics 85, 447–456, October 9, 2009 447
in animal models.25–29 In the absence of NT-4, the retina
develops normally in rodents, allowing the role of NT-4 to
be explored in pathological situations in the adult.30 NT-4
levels are upregulated in the retina after ischemic lesion,
and in animals lacking NT-4, retinal damage is more severe
than that in control animals.30 In addition, the human
NTF4 gene is located on chromosome 19q13.33,24 which
was previously identiﬁed as a putative glaucoma locus in
a genome-wide linkage scan.31 NTF4 is translated as
pre-pro-neurotrophin and cleaved to release the mature
active protein, which acts in solution as a noncovalently
linked homodimer triggering the phosphorylation of
TrkB, thus transducing its trophic effects in neurons.32 We
now report a mutation screen in NTF4 in three different
large cohorts of POAG patients, two from Germany and
one from the Netherlands, and their respective control
groups.We found a strong association of NT-4 variants pre-
dicted to alter protein function in the patients. We have
subsequently shown that themost frequent variant indeed
impairs TrkB signaling. Our ﬁndings implicate impaired
neuronal survival in the etiology of glaucoma.
Subjects and Methods
Patients and Control Groups
The study was approved by the ethical review board of themedical
faculty of the University of Erlangen-Nuremberg, the University
Hospital Tu¨bingen, the University Hospital Wu¨rzburg, and Eras-
mus University Rotterdam, the Netherlands, and was in accor-
dance with the tenets of the declaration of Helsinki. All subjects
gave informed consent before entering the study.
The discovery group of glaucoma patients consisted of 399
subjects of German (European) origin. Of these, 270 had primary
open-angle glaucoma (high-pressure POAG), 47 had juvenile
open-angle glaucoma (JOAG), and 82 had normal-tension open-
angle glaucoma (NTG). All individuals underwent standardized
clinical examinations for glaucoma at the Ophthalmologic
Department of the University of Erlangen-Nuremberg. The exam-
inations comprised slit-lamp biomicroscopy, gonioscopy, auto-
mated visual ﬁeld testing (Octopus G1, Interzeag, Switzerland),
fundus photography (Zeiss-Fundus camera, Germany), optional
laser scanning tomography (HRT I and II, Heidelberg Engineering,
Germany) of the disc, and 24 hr Goldmann-applanation intraoc-
ular pressure (IOP) tonometry proﬁle with ﬁve measurements.
Manifest high-tension POAG was deﬁned as the presence of glau-
comatous optic disc damage (in at least one eye), visual ﬁeld
defects in at least one eye, and IOP higher than 21 mmHg in
one eye without therapy. According to Jonas,33 stage 0 optic disc
was deﬁned as normal, stage I as vertical elongation of the cup
and neuroretinal rim loss at the 12 o’clock and 6 o’clock position,
stage II as focal rim loss, stage III and IV as advanced rim loss, and
stage V as absolute optic disc atrophy.34 Disc area was measured
with HRT or estimated with a Goldmann lens and a Haag-Streit
slit lamp. A pathologic visual ﬁeld was deﬁned by a pathologic
Bebie curve, three adjacent test points with more than 5 dB sensi-
tivity loss, or at least one point with more than 15 dB sensitiv-
ity loss.
Primary melanin dispersion, pseudoexfoliation and previously
raised IOP after trauma, a period of steroid administration, and448 The American Journal of Human Genetics 85, 447–456, Octobeuveitis were excluded as causes for secondary glaucoma. Glaucom-
atous optic nerve damage was deﬁned as focal or diffuse loss of the
neuroretinal rim or nerve ﬁber layer associated with a speciﬁc
visual ﬁeld defect. Patients who showed glaucomatous changes
of the optic disc and visual ﬁeld but no IOP elevation over 21
mmHg after 24 hr IOPmeasurement (sitting and supine body posi-
tion) without therapy were diagnosed as having NTG. Addition-
ally, in the NTG patient group, a neurological examination was
performed for exclusion of intracerebral expansion or malperfu-
sion. Stenosis of the aorta carotis interna was excluded by means
of sonography. Patients were classiﬁed as JOAG when age of onset
in the index case was below 40 years and no other ocular reason
for open-angle glaucoma was visible. At the time of examination,
the age of the patients ranged from 14 to 96 years, with a mean
of 66.9 5 13.4 years. In total, 178 patients (44.4%) had a family
history of glaucoma. All patients were also screened for myocilin
(MYOC), optineurin (OPTN), andWD repeat domain 36 (WDR36)35
mutations, as determined by direct sequencing of all coding regions.
The 376 control subjects were all of German origin and recruited
from the same geographic regions as those of the patients. In addi-
tion, control subjects were ophthalmologically examined and age
and sex matched to the patients. Thus, at the time of examination
and inclusion in this study, the age of control subjects ranged from
51 to 92 years, with a mean of 73.9 5 6.4 years. They had IOP
below 20 mmHg, no glaucomatous disc damage, and no family
history of glaucoma. Visual acuity was at least 0.8, or 20/25, and
the ocular media were clear for examination.
The ﬁrst replication group consisted of 282 unrelated patients,
224 with NTG and 58 with POAG. The age of the patients ranged
from 40 to 86 years, with amean of 64.85 11.9 years. The patients
were clinically investigated at the University Eye Hospital inWu¨rz-
burg and Tu¨bingen. Clinical details have been reported else-
where.36 Control DNA samples were obtained from 67 unrelated
subjects of German descent, selected with the use of the same
criteria described above.
The second replication group consisted of 211 POAG cases (age
range 56 to 94 years, with a mean of 75.5 5 7.4 years) from the
Rotterdam Study. The rationale and study design of this study
have been described elsewhere.37 Glaucoma diagnosis was based
on Goldmann kinetic perimetry (Haag Streit, Bern, Switzerland)
and on optical nerve head appearance. For details seeWolfs et al.38
The third replication cohort consisted of 69 POAG patients and
42 NTG patients who had been recruited in three local hospitals in
the Netherlands as part of the Genetic Research in Isolated Popu-
lations (GRIP) program.39,40 Ages ranged from 52 to 90 years, with
a mean age of 74.45 9.0. The diagnosis of glaucoma was made by
a glaucoma specialist and was based on a glaucomatous appear-
ance of the optic disc (notching or thinning of the neuroretinal
rim), combined with a matching glaucomatous visual ﬁeld defect.
Mutation Screening
Genomic DNA was prepared from peripheral blood samples by
a standard salting-out protocol and with the automated AutoGen-
Flex (Genelimited, UK) with the use of the Flexi-Gene Kit
(QIAGEN, Germany). Complete coding regions of the NTF4
gene, including ﬂanking intronic and UTR sequences, were ampli-
ﬁed by polymerase chain reaction (PCR) with the use of appro-
priate ampliﬁcation protocols. Primer sequences (depicted in Table
S1, available online) were selected with the use of Primer3 software
and were supplied from Invitrogen (Karlsruhe, Germany). Puriﬁed
PCR fragments were sequenced with Big Dye Termination Chem-
istry v. 3.1 (Applied Biosystems, ABI, Weiterstadt, Germany) on anr 9, 2009
automated capillary sequencer (ABI 3730 Genetic Analyzer, Wei-
terstadt, Germany). Each variant was conﬁrmed by a second inde-
pendent analysis. GenBank accession number NM_ 006179,
version NM_006179.3, was used as cDNA reference sequence
and NT_ 011109 as genomic reference sequence. We used
P34130 from the Swiss-Prot and Trembl database as reference pre-
proprotein sequence. Evolutionary conservation of nonsynony-
mous variants was investigated with protein sequence alignment
generated by ClustalW and compared with that presented by
Ensembl Genome Browser.
Structural Analysis and Molecular Modeling
Modeling of all NTF4 mutations except R209G was performed on
the basis of the crystal structure of the NTF4-TrkB complex (PDB
code: 1HCF41). Because R209 is not resolved in the NTF4-TrkB
crystal structure, the R209G mutation was modeled on the basis
of the NTF4 heterodimer with brain-derived neutrophic factor
(PDB code: 1B8M42). Mutations were inserted with the use of the
Sybyl 7.2 program package (Tripos) and subsequently reﬁned by
100 steps of energy minimization. Side chain interactions were
Figure 1. Location of NT-4 Amino Acid
Changes on Protein Structure and Evolu-
tionary Conservation
(A) Schematic representation of the
intron-exon organization of the NTF4
gene and of the derived protein. NT-4
mature protein (starting fromG81) is high-
lighted with gray transverse lines. All six
mutations identiﬁed in this study are
shown above the protein. Five variants
are located in the NGF domain, and one
is located in the N terminus of the prepro-
protein.
(B) DNA chromatograms of the mutation
sites.
(C) Multiple amino acid sequence align-
ments show evolutionary conservation of
mutated residues (shown in blue) among
mamalian species. Amino acid changes
are highlighted in red.
analyzed with the use of LigPlot,43 with
standard cutoff criteria used. The biophys-
ical properties of the N-terminal pro-
peptide, which contains the site of the
C7Y mutation, was investigated with the
ProtScale server, with standard settings
used.44
Recombinant NTF4
An NTF4 expression clone with a CMV
promoter was obtained from GeneCopoeia
(Germantown, MD, USA). The NTF4 insert
without a stop codon was then transferred
into an additional expression vector con-
tainingamycC-terminal fusiontag followed
byastopcodon(deliveredbyGeneCopoeia).
Mutagenesis
R206W-mycNT-4 andwild-type (WT)-myc
N-4 were obtained with the use of standard
protocols of the QuickChange II Site-Directed Mutagenesis
Kit (Stratagene, Amsterdam Zuidoost, The Netherlands). The
following oligonucleotides were used for the mutagenesis: 50-GCA
CACTCCTCAGCTGGACTGGCGAGCAGAAAC-30and 50-GTTTCT
GCTCGCCAGTCCAGCTGAGGAGTGTGC-30 (Invitrogen, Karls-
ruhe, Germany).
Production of Recombinant NT-4
COS-7 cells were transfected with the use of LipofectAmine2000
(Invitrogen, CA, USA) with 6 mg of empty vector or plasmids en-
coding WT NT-4, WT-myc NT-4, or mutant R206W-myc NT-4.
After 2 days, conditioned media were collected and concentrated
in Amicon 30,000 MWCO columns (Millipore, MA, USA). The
concentrations of WT and WT-myc NT-4 were determined by
immunoblotting with rabbit anti-NT-4 (1:500, sc-545, Santa
Cruz Biotechnology, CA, USA) with known concentrations of re-
combinant human NT-4 as standard puriﬁed from CHO-condi-
tioned medium (Genentech). The concentration of R206W-myc
NT-4 was determined by immunoblotting with goat anti-c-myc
(1:500, sc-789-G, Santa Cruz Biotechnology) and compared with
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TrkB-Expressing nnr5-PC12 Cells
nnr-5 PC12 cells45 were stably transfected with a cDNA encoding
full-length rat trkB. TrkB-expressing nnr5 PC12 cells (TrkB-nnr5
cells) were cultured on poly-D-lysine-coated plates and main-
tained in Dulbecco’s modiﬁed Eagle’s medium (GIBCO, Paisley,
Scotland) containing 0.1% or 0.5% fetal calf serum (GIBCO) for
TrkB activation assay or neurite outgrowth assay, respectively.
TrkB-Activation Assay
For quantiﬁcation of TrkB activation by neurotrophins, immuno-
blotting was performed with the use of anti-phospho-TrkA (1:500,
no. 9141, Cell Signaling Technology, MA, USA) or rabbit anti-pan
Trk (1:500, sc-139, Santa Cruz Biotechnology). Image analysis soft-
ware (ImageQuant, Molecular Dynamics, CA, USA) was used for
determination of the relative expression levels of proteins, and
the results are presented as the ratio of induced to basal levels.
Neurite-Outgrowth Assay
Neurite outgrowth was assessed by scoring the number of cells
bearing neurites in four randomly chosen areas per well; each
area contained approximately 80–100 cells. Cells bearing at least
one neurite with a minimal length corresponding to the diameter
of the cell body were positively scored. Four independent experi-
ments were performed for conﬁrmation of reproducibility.
Table 1. NTF4 Sequence Variants Found in Patients and Control
Individuals
Nucleotide Alteration Amino Acid Change Patients Controls
Discovery group
n ¼ 399 n ¼ 376
c.20G>A C7Y 1 0
c.250C>T E84K 1 0
c.263C>T A88V 1 0
c.269G>A R90H 1 0
c.616C>T R206W 4 0
c.617G>A R206Q 1 0
Subtotala 9 0
Replication group I
n ¼ 282 n ¼ 67
c.263C>T A88V 2 0
c.616C>T R206W 1 0
c.625C>G R209G 1 0
Replication group II
n ¼ 211 n ¼ 452
c.263C>T A88V 2 0
c.620C>G T207S 0 1
Totalb
n ¼ 892 n ¼ 895
15 1
a p < 0.004.
b p < 0.0002 (two-tailed Fischer’s exact test).450 The American Journal of Human Genetics 85, 447–456, OctobeStatistical Analysis
Statistical signiﬁcance was evaluated with one-way analysis of
variance followed by Newman-Keuls test for multiple groups,
and probability values of less than 5%were considered signiﬁcant.
Whole-Mount In Situ Hybridization and Microscopy
Retinal specimens were obtained from one human eye. One
normal donor eye (age 70 years, male without history of ocular
disease) was obtained at autopsy and processed within 6 hr after
death. Informed consent for tissue donation was obtained from
the patient, and the study protocol adhered to the tenets of the
Declaration of Helsinki for experiments involving human tissues.
The eyes were ﬁxed in 4% PFA/PBS for 1.5 hr. RNA in situ hybrid-
ization was performed on free-ﬂoating pieces of whole-mount
retina. For detection of NTF4, digoxigenin (DIG)-labeled RNA
probes were prepared with the use of components of the riboprobe
in vitro transcription systems (Promega, Mannheim, Germany)
and DIG-labeled UTP (Roche, Mannheim, Germany). NTF4
cDNA fragment was obtained from human retina mRNA by
reverse transcription coupled to PCR by the use of primers NTF4-
SF (50-CTGCAGCTGGCGGCAGTCC-30) and NTF4-SR (50-ATTAC
CCTCAAGTTGCTCCA-30). The resulting fragment, 466 bp long
and corresponding to nucleotide position 374-839 from the ﬁrst
ATG, was directly cloned into the pCR4-TOPO vector of the
TOPO-PCR-Cloning Kit (Invitrogen, Karlsruhe, Germany), in
accordance with the manufacturer’s instructions. We sequenced
isolated plasmids with the ABI Prism Big Dye Terminator cycle
sequencing kit and analyzed them on an ABI Genetic Analyzer
3730 (Applied Biosystems, Foster City, CA, USA) to ensure that
the constructs were correct. Two different clones containing the
NTF4 cDNA fragment in opposite orientation were chosen for
generation of the sense and antisense probes. Hybridization of
labeled probe was visualized with the use of alkaline phosphatase
conjugated anti-DIG (1:2.500), and the color reaction (5.5 hr,
30C) was developed with NBT/BCIP (Roche). We processed
treated and control retinas in parallel to ensure identical reaction
conditions. Finally, the retina was sectioned vertically at 18 mm on
a cryostat. For light microscopic analysis, sections were examined
and photographed with a Zeiss Axio Imager.Z1 (Zeiss, Jena,
Germany) ﬁtted with a Canon A620 digital camera. Images were
adjusted for contrast and brightness in Adobe Photoshop CS,
and panels were arranged in Corel Draw 11.
Results
Extensive screening for mutations in the complete coding
sequence of NTF4, including untranslated 50, 30, and in-
tronic ﬂanking regions, was performed in the discovery
groups of patients and control subjects. This systematic
mutation screen led to the identiﬁcationof six heterozygous
mutations leading to amino acid substitutions in NT-4;
namely, C7Y, E84K, A88V, R90H, R206W, and R206Q
(Figure1,Table1).Together, theaminoacid changesaccount
for over 2% of POAG in the discovery patient population
(9/399). No variants were found in the complete NTF4
coding region in 376matched, healthy control subjects (p<
0.004). All patients carrying anNT-4mutationwere sporadic
cases, and no other family members were affected to date.
The parents of all nine patients were deceased, and it is
unknownwhether they were also affected; thus, no familialr 9, 2009
Table 2. Phenotypic Characteristics of Patients with NT-4 Mutations
Patient
ID
Glaucoma
Type
NT-4
Mutation
Age at
Diagnosis
(Yrs) Sex Eye
Optic
Disc
(Jonas)
Disc
Area
(mm2)
Visual
Field
(md/clv)
Max IOP
(mmHg)
Chamber
Angle
(Shaffer) Additional Disease
Discovery group
99149 JOAG C7T 36 M L III 2.8 19.9/56.0 30 Open, III Arterial. hypertension
20532 POAG E84K 80 M R IV 2.4 23.4/- 22 Open, III Arterial. hypertension
99406 POAG A88V 48 M L IV 2.5 11.8/89.1 35 Open, III, mal
differentiated
Otherwise healthy
18780 POAG R90H 54 F L III-IV 3.9 11.0/48.8 40 Open, III, uv.
tissue
Type II Diabetes mellitus
20096 POAG R206Q 43 M L III 2.9 11.2/88.0 28 Open, III, uv.
tissue
Poliomyelitis vaccination
damage, otherwise healthy
7290 POAG R206W 53 F R III 2.5 8.2/61.7 25 Open, III History of Tubercolosis
11299 POAG R206W 51 M L II 2.6 3.7/ 9.6 34 Open, III Arterial. hypertension, goit
99394 POAG R206W 41 M L II 2.1 6.7/58.5 32 Open, III Otherwise healthy
6551 NTG R206W 51 M R III 3.0 5.9/116.9 16 Open III Arterial. hypertension
Replication group I
179 NTG A88V 42 F L I 2.8 2.0/2.6 12 Open III Arterial hypotonia
225 NTG A88V 49 F R I 2.4 0.2/4.1 19 Open III Arterial hypotonia
78 NTG R206W 78 F L II 2.1 11.7/48.1 15 Open III Arterial hypertension
65 NTG R209G 66 M R IV 2.1 22.3/55.6 20 Open III Arterial hypotonia
Replication group II
4134001 NTG A88V 79 F R II 3.6 Goldmann 21 Open Hypertension
4904001 NTG A88V 87 M L I NA Goldmann 13 Open Hypertension
Eye measurements refer to the worst affected eye (r, right; l, left), grade of optic disc atrophy according to Jonas, disc area (mm2), automated visual field (md dB/
clv dB2; in replication group II, Goldmann kinetic perimetry was used), maximum intraocular pressure (IOP mmHg), width of chamber angle (Shaffer’s scale; in
replication group II according to Von Herik).segregation could be studied. All ninepatientswerenegative
for MYOC, OPTN, CYP1B1, and WDR3646 mutations. The
mutation-positive patient group comprised individuals
with both late juvenile and adult-onset POAG, with age at
diagnosis varying from 36 to 80 years (Table 2). Seven had
elevated (maximum) IOP ranging from 25 to 40 mmHg,
whereas two had pressure measurements in the normal
range: 16 and 20mmHg. Apart fromglaucoma, patients pre-
sented without neurological manifestations, and arterial
hypertension was the only other abnormal feature, found
in four of them.
To replicate the observed data, we screened the complete
NTF4 coding region in an additional German cohort of 282
glaucoma patients and 67 control subjects. Two amino
acid changes, A88V and R206W, previously identiﬁed in
the discovery group, as well as an additional one, R209G,
were detected in four unrelated patients (Table 1). Two
patients suffered from progressed NTG and two from
beginning NTG (Table 2). It is important to note that no
variants leading to amino acid changes were detected in
all control individuals apart from a single one, a variant
leading to the same amino acid, D196D, found in oneThe Amerperson of the control replication cohort. In addition, one
known polymorphism in the 30 untranslated region
(rs11669977) was identiﬁed in patients as well in control
individuals of either discovery or replication groups. This
is not surprising, given that NTF4 is evolutionarily
conserved.47 In the second replication group, originating
from The Netherlands, two patients carried one NTF4
mutation (A88V). The control group was population based
and had not been ophthalmologically examined, unlike
the other two German groups. In this group, variant
T207S, not previously found in the patient groups, was
identiﬁed in one individual.
Altogether, we identiﬁed a total of 15 glaucoma patients
(1.7%) carrying an NTF4 mutation but only one person
carryinng the mutation in the three control groups (p <
0.0002; Table 1). The identiﬁed mutations are located in
themature domain of the NT-4 protein, with the exception
ofmutation C7Y, which is located in the N-terminal part of
the pro-part of the NT-4 protein (Figure 1A). All affected
amino acid positions show strong evolutionary conserva-
tion among orthologs in chimpanzee, dog, mouse, and
rat (Figure 1C).ican Journal of Human Genetics 85, 447–456, October 9, 2009 451
Molecular modeling based on the known homodimeric
NT-4 crystal structure in complex with its receptor
TrkB41,42 predicts that the identiﬁed mutations affect resi-
dues of the TrkB binding site (E84, A88, R90) or residues
relevant for the stabilization of the tertiary structure of
NT-4 (R206, R209) (Figure 2 and Figure 3). Thus, mutated
residues are likely to disrupt several interactions that
appear crucial for the formation and stabilization of this
complex (Figure 3).
For the mutation C7Y, located in the N-terminal part of
the unprocessed protein, no molecular modeling was
possible because no three-dimensional structural informa-
tion is available for this region. Analysis of the biophysical
properties of the pro-peptide, based on the common
hydrophathy scale,48 revealed that the C7Y mutation
causes a signiﬁcant decrease in the hydrophobicity of the
pro-peptide. The hydrophobic region of signal peptides
was shown to be a determinant for signal recognition
particle and protein translocation across the endoplas-
matic reticulum membrane.49 Thus, we postulate that
the C7Y mutation, which signiﬁcantly reduces the hydro-
phobicity of the pro-region, could impair the cleavage and/
or transport process, leading to a decreased concentration
or stability of NT-4.
The possibility that themost frequentmutation, R206W,
may reduce TrkB activation was tested by comparing the
activity of recombinant WT versus mutant NT-4 (Figures
Figure 2. Location of the Mutations in the Crystal Structure of
the NT-4-TrkB Complex
The two chains of the dimeric NT-4 are colored in cyan and blue,
respectively. The sites of the mutations are highlighted by
magenta balls (prime symbols denote residues of the second
subunit), indicating that these residues are located within or close
to the TrkB binding interface. TrkB domains bound by NT-4 are
colored in red and orange. Residue R209, which is C-terminally
adjacent to R206, is not resolved in this crystal structure. There-
fore, the approximate position of this residue is indicated in accor-
dance with another NT-4 structure,42 in which the respective
region is better resolved. The latter structure also provided the
basis for the detailed analysis of the R209G mutation shown in
Figure 3E.452 The American Journal of Human Genetics 85, 447–456, October4A–4C). These experiments revealed that the R206W
mutation has a reduced ability to activate TrkB, as
measured by tyrosine phosphorylation of the receptor
(Figure 4C). The functional consequences in terms of neu-
rotrophic activity were assessed with the use of a PC12-
based assay with cells stably expressing the TrkB receptor.
At concentrations identical toWTNT-4, R206Wwas signif-
icantly less active, as measured by the ﬁber-outgrowth
response (Figure 4D) that can readily be quantiﬁed with
this assay system (Figure 4E).
Finally, we tested for the presence and localization of
NTF4 in the adult retina by in situ hybridization (Figure 5).
Given the fact that glaucoma typically develops in the
elderly, NTF4 would be expected to be expressed in the
adult retina if it is to play a direct role in the pathogenesis
of glaucoma.We obtained a human retina a few hours after
the death of a 70-year-old patient with no previous history
of eye disease. In situ hybridization detected a speciﬁc
NTF4 signal that could clearly be localized to the ganglion
cell layer (Figure 5A), conﬁrming recent ﬁndings.50
Discussion
We hypothesized that retinal ganglion cell loss in POAG is
not mainly due to elevated intraocular pressure but that
factors compromising survival of such cells may also be
involved. We therefore screened NTF4 for mutations in
POAG on the basis of its function as a neurotrophic factor
protecting neurons. We sequenced the entire coding
sequence in a large cohort of POAG patients because we ex-
pected to ﬁnd only rare variants in few patients, in line
with previous ﬁndings in other glaucoma genes. We were
surprised to ﬁnd different missense variants in NTF4 in
almost 2% of cases, because to our knowledge, no such
variants had ever been described before. When we attemp-
ted replication of our ﬁndings in a second cohort of
German POAG patients, we likewise found missense vari-
ants at a similar frequency, thus conﬁrming our hypothesis
of a link betweenNT-4 and neuroprotection.We also inves-
tigated two ophthalmologically examined cohorts of
control individuals but did not ﬁnd a single missense
variant. To further validate our ﬁndings, we screened
a third POAG cohort from The Netherlands. Among 211
POAG cases from the Rotterdam Study, we found one
previously discovered variant in two patients (0.9%). In
this instance, a population-based cohort was used as
control, although these individuals were not investigated
for glaucoma. Thus, on the basis of the incidence of the
disease, we can expect at least ﬁve individuals from this
group to develop glaucoma during their lifetime. Not
unexpectedly, we found one person (0.2%) carrying an
additional missense variant, likely to have similar effect
as the previously identiﬁed ones. Overall, 15 patients
(1.7%) but only one control individual (0.1%) carried
a missense variant (p ¼ 0.0002), thus giving strong genetic
evidence that NTF4 variants are associated with POAG.9, 2009
Figure 3. Predicted Effects of NT-4 Amino Acid Changes onNT-4
Structure and Interaction with TrkB
Contacts formed by the WT residues (left) and effects of the muta-
tions (right). Residues of TrkB are denoted in italics.
(A) Effect of the E84K mutation: The side chain of E84 is oriented
toward the solvent. K84 is expected to adopt a different orienta-
tion as a result of electrostatic attraction by E293 of TrkB (green
dotted line). As a consequence, the contacts from NTF4 residues
81–84, representing the N terminus of mature NT-4 to TrkB, will
be disrupted (indicated by the broken line for the protein back-
bone).
(B) Effect of the A88V mutation. The larger size of the V88 side
chain results in steric clashes with L94 (red arrows), most probably
causing structural rearrangement of the binding region and thus
a poorer ﬁt to the receptor.
(C) Effect of the R90H mutation: R90 stacks on the side chain of
H343 from TrkB. The shorter side chain of H90 results in poorer
stacking in the mutant, suggesting a weaker binding.The AmerOn the basis of molecular modeling, all NT-4 variants
were predicted to affect either dimer stability of NT-4 or
interaction between the NT-4 dimer and its receptor, TrkB,
suggesting that these are bona ﬁde mutations. For the
most frequent variant, R206W, we demonstrated with
in vitro experiments that, indeed, both ligand-mediated
TrkB signaling and neurite outgrowth are impaired. This
suggests that these variants have a subtle but signiﬁcant
effect on neuronal survival. The effect is probably small
and might be compensated for during many years. Age
and/orother risk factorsmightbe required formanifestation
of the disease, in line with POAG being a late-onset disease.
We are not aware of previous reports onmutations in the
neurotrophin-4 gene (NTF4), and our results suggest an
essential role of the neurotrophin signaling system in pre-
venting neuronal degeneration in humans. Taken
together, these results suggest a relevant pathway in the
pathophysiology of glaucoma. They complement the
previous ﬁndings in rodents that a chronic reduction of
TrkB levels leads to a progressive loss of RGCs that becomes
apparent only in the adult.51 Likewise, a chronic, subop-
timal activation of TrkB resulting from the secretion of
a mutated form of NT-4 may lead to the progressive loss
of retinal ganglion cells, a ﬁnding that may open the possi-
bility of treating glaucoma by using agents activating TrkB.
In addition, these and previous data support the hypoth-
esis that POAG is characterized by a high locus and allelic
heterogeneity with different rare variants in numerous
genes. In fact, rare mutations with low frequencies have
also been reported for the other known glaucoma genes,
such asMYOC52 andWDR36.46 Jointly, these observations
suggest that POAG belongs to the same category of traits
under the ‘‘frequent disease-rare variant’’ hypothesis,
such as epilepsy53 and macular degeneration,54 with rare,
highly penetrant variants in numerous genes, some
familial but most occurring sporadically.55,56 This could
explain the so-far-elusive quest for identiﬁcation of more
glaucoma genes and would have important consequences
for the design of future studies aimed at unraveling the
molecular basis of this blinding disease.
Supplemental Data
Supplemental Data include one table containing the list of primers
used in this work and can be found with this article online at
http://www.cell.com/AJHG.
(D) Effect of the R206W and R206Q mutations: R206 forms
hydrogen bonds (green dotted lines) to the backbone carbonyl
of R163, thus stabilizing the three-dimensional structure of
NT-4 in a region close to the receptor binding site. In the
R206Q mutant, only one hydrogen bond can be formed,
whereas no hydrogen bonds can be formed in the R206W
mutant because of the length and chemical properties of the
W side chain.
(E) Effect of the R209G mutation: R209 forms a hydrogen bond
(green dotted line) to the backbone carbonyl of R164, thereby
stabilizing the three-dimensional structure of NT-4 in a fashion
similar to that of R206 (see panel D).ican Journal of Human Genetics 85, 447–456, October 9, 2009 453
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Figure 4. R206W-myc NT-4 Shows Decreased TrkB Activation
and Neurite Outgrowth in Comparison to WT-myc NT-4
(A) Treatment of TrkB-nnr5 cells with BDNF and NT-4 for 10 min
similarly induced TrkB phosphorylation, whereas NT-3 was less
active and NGF was inactive (100 ng/ml, respectively).
(B) Treatment with R206W-myc NT-4 for 10 min induced TrkB
activation signiﬁcantly less than WT and WT-myc NT-4 (10 ng/
ml, respectively).
(C) Densitometry analysis of ‘‘phospho-TrkB’’ was performed after
immunoblotting in (B). Data represent mean 5 SEM (n ¼ 4). ***
indicates p < 0.001 versus untreated, and ### indicates p <
0.001 versus R206W-myc NT-4.
(D) Representative phase contrast images of TrkB-nnr5 cells treated
with WT-myc or R206W-myc NT-4 (10 ng/ml) for 2 days. Scale bar
represents 10 mm.
(E) Graph shows the percentage of cells with neurites. TrkB-nnr5
cells were treated with WT, WT-myc, or R206W-myc NT-4 at 1 or
10 ng/ml for 2 days. Data represent mean 5 SEM (n ¼ 3). * indi-
cates p < 0.05, *** indicates p < 0.001 versus untreated, and ###
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